SCHEMBL909855

SCHEMBL909855

CCCCC(CCCC)c1ccc(O)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 9/20 0.58
ESR2 Q92731 6/20 0.58
ADORA3 P0DMS8 3/20 0.50
SLC6A2 P23975 3/20 0.50
SLC6A3 Q01959 3/20 0.50
LMNA P02545 2/20 0.50
CHRM2 P08172 2/20 0.50
CYP3A4 P08684 2/20 0.50
CHRM1 P11229 2/20 0.50
PTGS1 P23219 2/20 0.50
CYP1A2 P05177 1/20 0.50
PGR P06401 1/20 0.50
AR P10275 1/20 0.50
CYP2D6 P10635 1/20 0.50
MAPT P10636 1/20 0.50
CYP2C9 P11712 1/20 0.50
ALOX15 P16050 1/20 0.50
DRD1 P21728 1/20 0.50
TBXA2R P21731 1/20 0.50
CYP2C19 P33261 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1851402 0.96 ESR1 (0.65) ESR1ESR2ADORA3SLC6A2SLC6A3
SCHEMBL25272659 0.96 ESR1 (0.55) ESR1ESR2ADORA3SLC6A2SLC6A3
SCHEMBL27788605 0.94 ESR1 (0.53) ESR1ESR2ADORA3SLC6A2SLC6A3
SCHEMBL5046756 0.94 ESR1 (0.53) ESR1ESR2ADORA3SLC6A2SLC6A3
SCHEMBL27766911 0.94 ESR1 (0.53) ESR1ESR2ADORA3SLC6A2SLC6A3
SCHEMBL17260545 0.94 ESR1 (0.53) ESR1ESR2ADORA3SLC6A2SLC6A3
SCHEMBL3643220 0.94 ESR1 (0.53) ESR1ESR2ADORA3SLC6A2SLC6A3
SCHEMBL9354788 0.94 ESR1 (0.53) ESR1ESR2ADORA3SLC6A2SLC6A3
SCHEMBL27767006 0.94 ESR1 (0.53) ESR1ESR2ADORA3SLC6A2SLC6A3
SCHEMBL27788604 0.94 ESR1 (0.53) ESR1ESR2ADORA3SLC6A2SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021115628-A1 METHOD FOR PRODUCING PLATELET-SHAPED EFFECT PIGMENTS GIESECKE+DEVRIENT CURRENCY TECHNOLOGY GMBH (DE) 2021-06-17 WO claimed
US-20110002817-A1 FUEL COMPOSITION ON H2O2-BASIS, METHOD FOR PRODUCING SUCH A FUEL COMPOSITION AND DEVICES FOR ITS UTILIZATION INNOSUISSE DEVELOPMENT AG (CH) 2011-01-06 US claimed
EP-2235143-A1 FUEL COMPOSITION ON H2O2-BASIS, METHOD FOR PRODUCING SUCH A FUEL COMPOSITION AND DEVICES FOR ITS UTILIZATION Innosuisse Development AG (CH) 2010-10-06 EP claimed
WO-2009086933-A1 FUEL COMPOSITION ON H2O2-BASIS, METHOD FOR PRODUCING SUCH A FUEL COMPOSITION AND DEVICES FOR ITS UTILIZATION JENEY PETER (CH) 2009-07-16 WO claimed
EP-2049455-A1 FUEL ON H2O2-BASIS AND APPARATUS FOR ITS UTILIZATION AS ROCKET FUEL AND FUEL FOR ROTOR TIP ENGINES Jeney, Peter (CH) 2009-04-22 EP claimed
WO-2008006228-A1 FUEL ON H2O2-BASIS AND APPARATUS FOR ITS UTILIZATION AS ROCKET FUEL AND FUEL FOR ROTOR TIP ENGINES JENEY PETER (CH) 2008-01-17 WO claimed
US-5578557-A OIL WITH N-ACYLAMINO SARCOSINE, IMIDAZOLINE AND AMINE PHOSPHATE LYONDELL PETROCHEMICAL COMPANY (US) 1996-11-26 US claimed
US-4234733-A PHENOL, ALIPHATIC ESTER OR ETHER, CARBON MONOXIDE MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 1980-11-18 US claimed
WO-2026105727-A1 FORMULATION FOR TREATING SPINAL CORD DISEASE IN DOG AND METHOD FOR TREATING SPINAL CORD DISEASE IN DOG 東レ株式会社 2026-05-21 WO disclosed
WO-2026087658-A1 RELEASE COAT FORMULATION, METHOD FOR PRODUCING PIGMENTS OR FOIL SECURITY FEATURES GIESECKE+DEVRIENT CURRENCY TECHNOLOGY GMBH (DE) 2026-04-30 WO disclosed
EP-4356908-B1 METHOD FOR TREATING FELINE WITH CHRONIC KIDNEY DISEASE TORAY INDUSTRIES (JP) 2025-10-22 EP disclosed
US-12305041-B2 Method for producing platelet-shaped pigments GIESECKE+DEVRIENT CURRENCY TECHNOLOGY GMBH (DE) 2025-05-20 US disclosed
EP-4215580-B1 POLYMER COMPOSITION FOR MANUFACTURING LARGE CONTAINER CONTAINING HIGH-DENSITY POLYETHYLENE RECOVERED FROM SECONDARY BATTERY SEPARATOR AND LARGE CONTAINER MANUFACTURED USING THE SAME SK INNOVATION CO LTD (KR) 2025-03-05 EP disclosed
US-20240425448-A1 METHOD FOR PRODUCING ISOCYANATE COMPOUND, METHOD FOR PRODUCING CARBAMATE COMPOUND, METHOD FOR RECOVERING AMINE COMPOUND, AND ISOCYANATE COMPOSITION ASAHI KASEI KABUSHIKI KAISHA (JP) 2024-12-26 US disclosed
EP-0138232-B1 COMPOSITION FOR PRODUCING PLASTIC OR HARD MATERIALS FOR THE DENTAL INDUSTRY, (DENTAL) MEDICINE AND RELATED USE, PROCESS FOR ITS PREPARATION AND ITS USE Hofacker Freifrau von Nostitz, Frauke (DE) 1990-09-05 EP disclosed
US-4759798-A Mixing substrate selected from monomeric, polymeric or copolymeric acrylic or methacrylic ester, hardener and jojoba oil NOSTITZ F VON (DE) 1988-07-26 US disclosed
EP-0138232-A2 Composition for producing plastic or hard materials for the dental industry, (dental) medicine and related use, process for its preparation and its use Hofacker Freifrau von Nostitz, Frauke (DE) 1985-04-24 EP disclosed
US-4234733-A PHENOL, ALIPHATIC ESTER OR ETHER, CARBON MONOXIDE MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 1980-11-18 US disclosed
US-4124750-A DIENE POLYMER CROSSLINKED WITH A DIHYDRAZIDE COMPOUND THE GOODYEAR TIRE & RUBBER COMPANY (US) 1978-11-07 US disclosed
US-4103077-A Green strength of synthetic elastomers THE GOODYEAR TIRE & RUBBER COMPANY (US) 1978-07-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240425448-A1 METHOD FOR PRODUCING ISOCYANATE COMPOUND, METHOD FOR PRODUCING CARBAMATE COMPOUND, METHOD FOR RECOVERING AMINE COMPOUND, AND ISOCYANATE COMPOSITION IDH3A, CA7, C9 ESR1 2029/4885ESR2 3415/4885ADORA3 3687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.